Abstract: |
Curative therapies for HL have evolved over decades from radiation based therapy to combined modality therapy with radiation and chemotherapy. The treatment of cHL has changed to balance toxicity with cure rates. Over the last 20 years, the biology of HL continues to unravel with detailed understanding of the cell of origin, genomic composition of HRS cells and the contributions of the microenvironment toward HRS survival. This knowledge will contribute to the next advance in treatment, which will incorporate image-guided risk stratification and optimizing novel therapies to disrupt HRS dependency on the microenvironment. © 2015 Future Medicine Ltd. All rights reserved. |